Hologic to Acquire Breast Cancer Test Firm Reveal Genomics
The medical technology company aims to bolster its oncology diagnostics portfolio through the acquisition of the Spanish developer.
Updated on Oct. 20, 2026 in Biotech
Live Poll
Do you trust that consolidation among medical testing companies will improve your access to cancer care?
Hologic has signed a definitive agreement to acquire Barcelona-based Reveal Genomics. The move is designed to expand Hologic's oncology diagnostics offerings for patients with breast cancer.
Why it matters
The acquisition integrates new diagnostic capabilities into Hologic's existing portfolio. This combined offering is expected to help medical professionals better inform treatment decisions for more women.
Hologic utilizes machine learning and advanced computer applications to process and analyze complex cancer data sets. This acquisition brings the Reveal Genomics HER2DX test for HER2-positive breast cancer under the same corporate umbrella as Hologic's Breast Cancer Index.
The players
Hologic
A medical technology company based in Marlborough, Massachusetts, that focuses on women's health and diagnostic solutions.
Reveal Genomics
A biotech firm headquartered in Barcelona, Spain, that specializes in the development of breast cancer diagnostic tests.
The details
Hologic produces the Breast Cancer Index test specifically for HR+ early-stage breast cancer patients. The deal remains subject to standard Spanish regulatory approval and customary closing conditions.
Timeline
October 20, 2026: Hologic announced the definitive acquisition agreement.
The Tech Race
This acquisition reflects a broader consolidation trend in the biotech sector as major diagnostics firms compete to offer comprehensive, data-driven oncology platforms. By integrating specialized tests like HER2DX, companies are shifting away from standalone products toward unified diagnostic suites.
Patients may eventually see improved accessibility to integrated diagnostic insights that help clarify breast cancer treatment paths. The merger aims to streamline the availability of specialized testing through the expanded Hologic oncology network.
The takeaway
The move signals a growing emphasis on high-precision diagnostics powered by machine learning to manage complex cancer cases. Patients should discuss new diagnostic options with their oncologists to determine if updated testing protocols are relevant to their treatment plans.
Further reading
Learn more about the latest industry developments in Biotech.
Live Poll
Do you trust that consolidation among medical testing companies will improve your access to cancer care?
